# US 2002/0160450 A1 · Methods and compositions for increasing protein yield from a cell culture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0160450 A1
- Document ID: US20020160450A1
- Status: Published application
- Kind: A1
- Application number: 09/935,194
- Filed: 2001-08-21
- Published: 2002-10-31
- Earliest claimed: 2000-08-21
- Assignees: ClonexDevelopment, Inc.
- Inventors: Todd Bucciarelli; Victor Levenson; Thomas Primiano
- Web page: https://patentgrep.com/patent/US20020160450A1

## CPC

- C12N 15/85: for animal cells
- C07K 14/4738: {Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR (cell cycle dependent kinases C12N9/12)}
- C12N 2830/006: tet repressible
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are compositions and methods for increasing protein production from a cell culture. By switching the cells from a replicative to a productive state (RP switch), protein biosynthesis is extended. The productive state is a pseudo-senescent state. This pseudo-senescent state can be induced by transforming the cells with a vector expressing a cell cycle inhibitor. Expression of the cell cycle inhibitor within the cell, because it does not cause cell death, allows for cells to be maintained in culture for longer periods. The invention allows for controlled enhanced protein biosynthetic productivity of cell lines for commercial and research purposes.

## Claims

### Claim 1

A method of increasing yield of a protein from a cell culture, comprising:
(a) causing a pseudo-senescent state in one or more cells in the cell culture; and
(b) collecting a protein fraction from the cell culture.

### Claim 2 (depends on 1)

The method of claim 1, wherein the protein is a secreted protein.

### Claim 3 (depends on 2)

The method of claim 2, wherein the protein is an antibody.

### Claim 4 (depends on 2)

The method of claim 2, wherein the protein fraction is collected from the cell culture medium.

### Claim 5 (depends on 1)

The method of claim 1, wherein the protein is an intracellular protein.

### Claim 6 (depends on 1)

The method of claim 1, wherein the protein is a membrane protein.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cell culture is a eukaryotic cell culture

### Claim 8 (depends on 1)

The method of claim 1, wherein the cell culture is a mammalian cell culture.

### Claim 9 (depends on 8)

The method of claim 8, wherein the mammalian cell is contact-dependent for growth.

### Claim 10 (depends on 9)

The method of claim 9, wherein the mammalian cell is a hybridoma.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pseudo-senescent state is caused by contacting a cell with a composition that inhibits cell proliferation.

### Claim 12 (depends on 11)

The method of claim 11, wherein the composition comprises an expression vector.

### Claim 13 (depends on 11)

The method of claim 11, wherein the expression vector comprises an inducible transcription regulation element.

### Claim 14 (depends on 13)

The method of claim 13, wherein the transcription regulation element comprises a tetracycline operator element.

### Claim 15 (depends on 14)

The method of claim 14, wherein the transcription regulation element comprises a plurality of tetracycline operator elements.

### Claim 16 (depends on 15)

The method of claim 15, wherein the tetracycline operator elements are arranged such that two phased tetracycline operators are downstream from a TATA sequence and two phased tetracycline operators are upstream of the TATA sequence.

### Claim 17 (depends on 12)

The method of claim 12, wherein the expression vector encodes a cyclin-dependent kinase inhibitor.

### Claim 18 (depends on 17)

The method of claim 17, wherein the cyclin-dependent kinase inhibitor is a Cip/Kip family member.

### Claim 19 (depends on 18)

The method of claim 18, wherein the Cip/Kip family member is selected from the group consisting of p21, p27, and p57.

### Claim 20 (depends on 17)

The method of claim 17, wherein the cyclin-dependent kinase inhibitor is a INK4 family member.

### Claim 21 (depends on 20)

The method of claim 20, wherein the INK4 family member is selected from the group consisting of p15, p16, p18, and p19.

### Claim 22 (depends on 1)

The method of claim 1, wherein the pseudo-senescent state is caused by expression of one or more proteins encoded by one or more expression vectors.

### Claim 23 (depends on 22)

The method of claim 22, wherein the proteins are p16, p21, and p57.

### Claim 24 (depends on 23)

The method of claim 23, wherein the proteins are p16, p21, and p27.

### Claim 25

A method of increasing yield of a protein from a eukaryotic cell culture, comprising:
(a) contacting the cell culture with an expression vector which comprises an inducible transcription regulation element comprising a tetracycline operator element; and
(b) collecting a protein fraction from the cell culture.

### Claim 26

A transcriptional regulatory element comprising:
(a) a minimal promoter comprising a TATA sequence;
(b) two phased tetracycline operators downstream from the TATA sequence; and
(c) two phased tetracycline operators upstream of the TATA sequence.

### Claim 27 (depends on 26)

The transcriptional regulatory element of claim 26, wherein the two phased tetracycline operators downstream from the TATA sequence are 21 basepairs downstream from the TATA sequence.

### Claim 28 (depends on 26)

The transcriptional regulatory element of claim 26, wherein the two phased tetracycline operators upstream from the TATA sequence are 11 basepairs upstream from the TATA sequence.

### Claim 29 (depends on 26)

The transcriptional regulatory element of claim 26, wherein:
(a) the two phased tetracycline operators downstream from the TATA sequence are 21 basepairs downstream from the TATA sequence; and
(b) the two phased tetracycline operators upstream from the TATA sequence are 11 basepairs upstream from the TATA sequence.

### Claim 30 (depends on 26)

The transcriptional regulatory element of claim 26, wherein the minimal promoter is a CMV promoter.

### Claim 31

An expression vector comprising:
(a) a minimal promoter comprising a TATA sequence;
(b) two phased tetracycline operators downstream from the TATA sequence; and
(c) two phased tetracycline operators upstream of the TATA sequence.

### Claim 32 (depends on 31)

The expression vector of claim 31, wherein the two phased tetracycline operators downstream from the TATA sequence are 21 basepairs downstream from the TATA sequence.

### Claim 33 (depends on 31)

The expression vector of claim 31, wherein the two phased tetracycline operators upstream from the TATA sequence are 11 basepairs upstream from the TATA sequence.

### Claim 34 (depends on 31)

The expression vector of claim 31, wherein:
(a) the two phased tetracycline operators downstream from the TATA sequence are 21 basepairs downstream from the TATA sequence; and
(b) the two phased tetracycline operators upstream from the TATA sequence are 11 basepairs upstream from the TATA sequence.

### Claim 35 (depends on 31)

The expression vector of claim 31, wherein the minimal promoter is a CMV promoter.

### Claim 36 (depends on 31)

The expression vector of claim 31, wherein the vector is a viral vector.

### Claim 37 (depends on 36)

The expression vector of claim 36, wherein the viral vector is a retroviral vector.

### Claim 38 (depends on 37)

The expression vector of claim 37, wherein the retroviral vector is a Moloney strain murine leukemia virus vector.

### Claim 39 (depends on 31)

The expression vector of claim 31, further comprising a gene operably linked to the promoter.

### Claim 40 (depends on 39)

The expression vector of claim 39, wherein the gene encodes a cyclin dependent kinase inhibitor.

### Claim 41 (depends on 40)

The expression vector of claim 40, wherein the cyclin dependent kinase inhibitor is selected from the group consisting of p21, p27, p57, p15, p16, p18, and p19.

### Claim 42 (depends on 41)

The expression vector of claim 41, wherein the vector encodes more than one cyclin-dependent kinase selected from the group consisting of p21, p27, p57, p15, p16, p18, and p19.
